Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402168 · ClinicalTrials.gov registry record · Phase 2
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT00402168 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 173 participants.
The verdict
NCT00402168, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied
Interventions
- DRUG Tacrolimus
- DRUG Cyclosporine A
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402168
The ClinicalTrials.gov registry entry for NCT00402168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT00402168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402168 about?
NCT00402168 is a clinical study titled "A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids". The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety and tolerability of this treatment will also be studied
What is the current status of trial NCT00402168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2007-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00402168?
The interventions under investigation include: Tacrolimus (DRUG), Cyclosporine A (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT00402168?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.